Blume Capital Management »

Crispr Therapeutics shares owned by Blume Capital Management

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Blume Capital Management from 13F filings

Historical chart of Blume Capital Management investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Blume Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Blume Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $2.7k 50 54.54

More positions owned by Blume Capital Management

Alphabet Cap Stk Cl C (GOOG)
Micron Technology (MU)
Apple (AAPL)
Vanguard Instl Index 0 3 Mo Tr Bi Etf (VBIL)
Dimensional Etf Trust Intl Core Equity (DFIC)
Applied Materials (AMAT)
Citigroup Com New (C)
Vanguard Malvern Fds Core Bd Etf (VCRB)
Amazon (AMZN)
Dimensional Etf Trust Core Fixe In Etf (DFCF)
Select Sector Spdr Tr St Str Energ Etf (XLE)
Charles Schwab Corporation (SCHW)
Freeport Mcmoran CL B (FCX)
Dimensional Etf Trust Emerging Mkts Co (DFEM)
J P Morgan Exchange Traded F Core Plus Bd Etf (JCPB)

View all positions for Blume Capital Management

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Orbis Allan Gray
Capital World Investors
State Street Corporation
GSK
Geode Capital Management
Sr One Capital Management
Two Sigma Investments
FMR
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
EcoR1 Capital
UBS Group
Capital Research and Management Company - Division 3

View all funds holding Crispr Therapeutics